Edwina Coghlan1, Tarek M Meniawy, Aime Munro, Max Bulsara, Colin Jr Stewart, Adeline Tan, M H Eleanor Koay, Daniel MaGee, Jim Codde, Jason Tan, Stuart G Salfinger, Ganendra R Mohan, Yee Leung, Cassandra B Nichols, Paul A Cohen. 1. *Bendat Family Comprehensive Cancer Centre, St John of God Subiaco Hospital, Subiaco; †Institute for Health Research, University of Notre Dame Australia, Fremantle; ‡School of Medicine and Pharmacology, University of Western Australia, Crawley; §Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands; ∥School of Women's and Infants' Health, University of Western Australia, Crawley; ¶Department of Histopathology, King Edward Memorial Hospital, Subiaco; #St John of God Pathology, St John of God Subiaco Hospital, Subiaco; **School of Medicine, University of Notre Dame Australia, Fremantle; ††WOMEN Centre, West Leederville; ‡‡Genetics Services of Western Australia, King Edward Memorial Hospital, Subiaco, Western Australia; and §§Inherited Cancer Connect Partnership, Familial Cancer Centre, Peter MacCallum Cancer Centre, Victoria, Southeast Australia, Australia.
Abstract
OBJECTIVE: Our objective was to validate the prognostic role of the chemotherapy response score (CRS), which has been proposed for measuring tumor response to neoadjuvant chemotherapy in patients with high-grade serous tubo-ovarian carcinoma, in predicting progression-free survival (PFS) and overall survival (OS). METHODS: A retrospective cohort study was conducted of patients with advanced high-grade serous tubo-ovarian carcinoma diagnosed between January 1, 2010, and December 31, 2014, and treated with neoadjuvant chemotherapy. Treatment-related tumor regression was determined according to the 3-tier CRS, and results were compared with standard clinicopathological variables. Survival analysis was performed using Cox proportional hazards models and the log-rank test. RESULTS: Seventy-one patients were eligible for analysis. Median OS was 25.5 months. Fifty-eight patients (82%) had disease recurrence and 32 (45%) had died at study census. Of the 71 patients, 19, 29, and 23 patients had a CRS of 1, 2, and 3, respectively. On univariate analysis, the CRS significantly predicted PFS (hazard ratio [HR], 3.77; 95% confidence interval [CI], 1.83-7.78; P = 0.000) and OS (HR, 2.81; 95% CI, 1.16-6.79; P = 0.022). In a multivariate model, the CRS was significantly associated with PFS (HR, 2.81; 95% CI, 1.16-6.79; P = 0.022) but not with OS (HR, 2.39; 95% CI, 0.47-3.08; P = 0.079). Patients with CRS of 1 and 2 combined were twice as likely to progress during the study period compared with patients with a CRS of 3 (HR, 2.0; 95% CI, 1.06-3.78; P = 0.032; median PFS, 16 vs 26 months). No significant association was observed for OS (CRS 1/2 vs 3; HR, 1.57; 95% CI, 0.68-3.65; P = 0.291). CONCLUSIONS: In this study, the CRS showed independent prognostic significance for PFS but not for OS.
OBJECTIVE: Our objective was to validate the prognostic role of the chemotherapy response score (CRS), which has been proposed for measuring tumor response to neoadjuvant chemotherapy in patients with high-grade serous tubo-ovarian carcinoma, in predicting progression-free survival (PFS) and overall survival (OS). METHODS: A retrospective cohort study was conducted of patients with advanced high-grade serous tubo-ovarian carcinoma diagnosed between January 1, 2010, and December 31, 2014, and treated with neoadjuvant chemotherapy. Treatment-related tumor regression was determined according to the 3-tier CRS, and results were compared with standard clinicopathological variables. Survival analysis was performed using Cox proportional hazards models and the log-rank test. RESULTS: Seventy-one patients were eligible for analysis. Median OS was 25.5 months. Fifty-eight patients (82%) had disease recurrence and 32 (45%) had died at study census. Of the 71 patients, 19, 29, and 23 patients had a CRS of 1, 2, and 3, respectively. On univariate analysis, the CRS significantly predicted PFS (hazard ratio [HR], 3.77; 95% confidence interval [CI], 1.83-7.78; P = 0.000) and OS (HR, 2.81; 95% CI, 1.16-6.79; P = 0.022). In a multivariate model, the CRS was significantly associated with PFS (HR, 2.81; 95% CI, 1.16-6.79; P = 0.022) but not with OS (HR, 2.39; 95% CI, 0.47-3.08; P = 0.079). Patients with CRS of 1 and 2 combined were twice as likely to progress during the study period compared with patients with a CRS of 3 (HR, 2.0; 95% CI, 1.06-3.78; P = 0.032; median PFS, 16 vs 26 months). No significant association was observed for OS (CRS 1/2 vs 3; HR, 1.57; 95% CI, 0.68-3.65; P = 0.291). CONCLUSIONS: In this study, the CRS showed independent prognostic significance for PFS but not for OS.
Authors: N M de Lange; N P M Ezendam; J S Kwon; I Vandenput; D Mirchandani; F Amant; L J M van der Putten; J M A Pijnenborg Journal: Curr Oncol Date: 2019-04-01 Impact factor: 3.677
Authors: Barrett C Lawson; Elizabeth D Euscher; Roland L Bassett; Jinsong Liu; Preetha Ramalingam; YanPing Zhong; Nicole D Fleming; Anais Malpica Journal: Am J Surg Pathol Date: 2020-02 Impact factor: 6.298
Authors: M Liontos; A Andrikopoulou; K Koutsoukos; C Markellos; E Skafida; O Fiste; M Kaparelou; N Thomakos; D Haidopoulos; A Rodolakis; M A Dimopoulos; F Zagouri Journal: J Ovarian Res Date: 2021-11-01 Impact factor: 4.234